Huang et al., suggest that the ratio between the reinvigoration of circulating CD8+T cells and the baseline tumor load positively correlates with clinical response to pembrolizumab and can serve as a response predictor for this drug [33]. This evidence concerns the gene CD8A and neoplasm.